Cargando…

Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease

OBJECTIVE: Long non‐coding RNA activated by DNA damage (lnc‐NORAD) modulates inflammation, lipid level, and atherosclerosis in various cardiovascular diseases. This study intended to investigate the dysregulated expression of lnc‐NORAD, and its linkage with clinical characteristics, inflammatory cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoyun, Kan, Xuetong, Shen, Jingjing, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701832/
https://www.ncbi.nlm.nih.gov/pubmed/36319574
http://dx.doi.org/10.1002/jcla.24717
_version_ 1784839627089117184
author Zhang, Xiaoyun
Kan, Xuetong
Shen, Jingjing
Li, Jian
author_facet Zhang, Xiaoyun
Kan, Xuetong
Shen, Jingjing
Li, Jian
author_sort Zhang, Xiaoyun
collection PubMed
description OBJECTIVE: Long non‐coding RNA activated by DNA damage (lnc‐NORAD) modulates inflammation, lipid level, and atherosclerosis in various cardiovascular diseases. This study intended to investigate the dysregulated expression of lnc‐NORAD, and its linkage with clinical characteristics, inflammatory cytokines, and accumulating major adverse cardiovascular events (MACE) in coronary heart disease (CHD) patients. METHODS: Totally, 160 CHD patients, 30 disease controls (DCs), and 30 healthy controls (HCs) were included. The reverse transcription‐quantitative polymerase chain reaction was used to detect lnc‐NORAD expression in peripheral blood mononuclear cell samples from all participants. Enzyme‐linked immunosorbent assay was applied to detect proinflammatory cytokines and adhesion molecules in CHD patients. Then, MACE was recorded during a median follow‐up of 12 (range: 1.0–27.0) months. RESULTS: Lnc‐NORAD was highest in CHD patients, followed by DCs, and lowest in HCs (p < 0.001). In CHD patients, lnc‐NORAD was positively linked with Gensini score (p = 0.001). Meanwhile, lnc‐NORAD was positively linked to C‐reactive protein (p = 0.023), tumor necrosis factor‐alpha (p = 0.016), interleukin (IL)‐6 (p = 0.003), IL‐8 (P = 0.018), and IL‐17A (p = 0.029). No relation of lnc‐NORAD with vascular cell adhesion molecule‐1 (p = 0.094) and intercellular adhesion molecule‐1 (p = 0.060) was found. Furthermore, lnc‐NORAD was positively related to total cholesterol (p = 0.014) and low‐density lipoprotein cholesterol (p = 0.004), whereas lnc‐NORAD was not linked to triglyceride (p = 0.103) and high‐density lipoprotein cholesterol (p = 0.533). However, lnc‐NORAD (high vs. low), and its higher quartiles were both not linked to accumulating MACE rate (p > 0.05). CONCLUSION: Increased lnc‐NORAD is linked with aggravated stenosis degree, inflammation status, and blood lipid in CHD patients. However, further validation is required.
format Online
Article
Text
id pubmed-9701832
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97018322022-11-28 Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease Zhang, Xiaoyun Kan, Xuetong Shen, Jingjing Li, Jian J Clin Lab Anal Research Articles OBJECTIVE: Long non‐coding RNA activated by DNA damage (lnc‐NORAD) modulates inflammation, lipid level, and atherosclerosis in various cardiovascular diseases. This study intended to investigate the dysregulated expression of lnc‐NORAD, and its linkage with clinical characteristics, inflammatory cytokines, and accumulating major adverse cardiovascular events (MACE) in coronary heart disease (CHD) patients. METHODS: Totally, 160 CHD patients, 30 disease controls (DCs), and 30 healthy controls (HCs) were included. The reverse transcription‐quantitative polymerase chain reaction was used to detect lnc‐NORAD expression in peripheral blood mononuclear cell samples from all participants. Enzyme‐linked immunosorbent assay was applied to detect proinflammatory cytokines and adhesion molecules in CHD patients. Then, MACE was recorded during a median follow‐up of 12 (range: 1.0–27.0) months. RESULTS: Lnc‐NORAD was highest in CHD patients, followed by DCs, and lowest in HCs (p < 0.001). In CHD patients, lnc‐NORAD was positively linked with Gensini score (p = 0.001). Meanwhile, lnc‐NORAD was positively linked to C‐reactive protein (p = 0.023), tumor necrosis factor‐alpha (p = 0.016), interleukin (IL)‐6 (p = 0.003), IL‐8 (P = 0.018), and IL‐17A (p = 0.029). No relation of lnc‐NORAD with vascular cell adhesion molecule‐1 (p = 0.094) and intercellular adhesion molecule‐1 (p = 0.060) was found. Furthermore, lnc‐NORAD was positively related to total cholesterol (p = 0.014) and low‐density lipoprotein cholesterol (p = 0.004), whereas lnc‐NORAD was not linked to triglyceride (p = 0.103) and high‐density lipoprotein cholesterol (p = 0.533). However, lnc‐NORAD (high vs. low), and its higher quartiles were both not linked to accumulating MACE rate (p > 0.05). CONCLUSION: Increased lnc‐NORAD is linked with aggravated stenosis degree, inflammation status, and blood lipid in CHD patients. However, further validation is required. John Wiley and Sons Inc. 2022-11-01 /pmc/articles/PMC9701832/ /pubmed/36319574 http://dx.doi.org/10.1002/jcla.24717 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Zhang, Xiaoyun
Kan, Xuetong
Shen, Jingjing
Li, Jian
Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
title Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
title_full Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
title_fullStr Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
title_full_unstemmed Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
title_short Increased long non‐coding RNA NORAD reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
title_sort increased long non‐coding rna norad reflects serious cardiovascular stenosis, aggravated inflammation status, and higher lipid level in coronary heart disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701832/
https://www.ncbi.nlm.nih.gov/pubmed/36319574
http://dx.doi.org/10.1002/jcla.24717
work_keys_str_mv AT zhangxiaoyun increasedlongnoncodingrnanoradreflectsseriouscardiovascularstenosisaggravatedinflammationstatusandhigherlipidlevelincoronaryheartdisease
AT kanxuetong increasedlongnoncodingrnanoradreflectsseriouscardiovascularstenosisaggravatedinflammationstatusandhigherlipidlevelincoronaryheartdisease
AT shenjingjing increasedlongnoncodingrnanoradreflectsseriouscardiovascularstenosisaggravatedinflammationstatusandhigherlipidlevelincoronaryheartdisease
AT lijian increasedlongnoncodingrnanoradreflectsseriouscardiovascularstenosisaggravatedinflammationstatusandhigherlipidlevelincoronaryheartdisease